123 related articles for article (PubMed ID: 19027240)
1. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
[TBL] [Abstract][Full Text] [Related]
2. Overcoming drug resistance in pancreatic cancer.
Long J; Zhang Y; Yu X; Yang J; LeBrun DG; Chen C; Yao Q; Li M
Expert Opin Ther Targets; 2011 Jul; 15(7):817-28. PubMed ID: 21391891
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeted approaches for treatment of pancreatic cancer.
Huang ZQ; Saluja AK; Dudeja V; Vickers SM; Buchsbaum DJ
Curr Pharm Des; 2011; 17(21):2221-38. PubMed ID: 21777178
[TBL] [Abstract][Full Text] [Related]
4. ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer.
Yu P; Luo S; Cai J; Li J; Peng C
Aging (Albany NY); 2022 Oct; 14(19):7941-7958. PubMed ID: 36214762
[TBL] [Abstract][Full Text] [Related]
5. SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis.
Gao Z; Wu J; Wu X; Zheng J; Ou Y
Open Med (Wars); 2020; 15(1):1072-1082. PubMed ID: 33336063
[TBL] [Abstract][Full Text] [Related]
6. Facilitating the Cellular Accumulation of Pt-Based Chemotherapeutic Drugs.
Lambert IH; Sørensen BH
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30071606
[TBL] [Abstract][Full Text] [Related]
7. Irradiated human endothelial progenitor cells induce bystander killing in human non-small cell lung and pancreatic cancer cells.
Turchan WT; Shapiro RH; Sevigny GV; Chin-Sinex H; Pruden B; Mendonca MS
Int J Radiat Biol; 2016 Aug; 92(8):427-33. PubMed ID: 27258472
[TBL] [Abstract][Full Text] [Related]
8. Ion channels and transporters in the development of drug resistance in cancer cells.
Hoffmann EK; Lambert IH
Philos Trans R Soc Lond B Biol Sci; 2014 Mar; 369(1638):20130109. PubMed ID: 24493757
[TBL] [Abstract][Full Text] [Related]
9. Interaction of tumour cells with their microenvironment: ion channels and cell adhesion molecules. A focus on pancreatic cancer.
Arcangeli A; Crociani O; Bencini L
Philos Trans R Soc Lond B Biol Sci; 2014 Mar; 369(1638):20130101. PubMed ID: 24493749
[TBL] [Abstract][Full Text] [Related]
10. Mucins and pancreatic cancer.
Jonckheere N; Skrypek N; Van Seuningen I
Cancers (Basel); 2010 Oct; 2(4):1794-812. PubMed ID: 24281201
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy.
Tamburrino A; Piro G; Carbone C; Tortora G; Melisi D
Front Pharmacol; 2013; 4():56. PubMed ID: 23641216
[TBL] [Abstract][Full Text] [Related]
12. Mucin-based targeted pancreatic cancer therapy.
Torres MP; Chakraborty S; Souchek J; Batra SK
Curr Pharm Des; 2012; 18(17):2472-81. PubMed ID: 22372499
[TBL] [Abstract][Full Text] [Related]
13. Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.
Wennier ST; Liu J; Li S; Rahman MM; Mona M; McFadden G
Mol Ther; 2012 Apr; 20(4):759-68. PubMed ID: 22233582
[TBL] [Abstract][Full Text] [Related]
14. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
Liu DL; Bu H; Li H; Chen H; Guo HC; Wang ZH; Tong HF; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2012 Apr; 40(4):1049-57. PubMed ID: 22159556
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination.
Rudin D; Li L; Niu N; Kalari KR; Gilbert JA; Ames MM; Wang L
J Drug Metab Toxicol; 2011 Feb; 2(107):1-10. PubMed ID: 21804948
[TBL] [Abstract][Full Text] [Related]
16. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.
Lister A; Nedjadi T; Kitteringham NR; Campbell F; Costello E; Lloyd B; Copple IM; Williams S; Owen A; Neoptolemos JP; Goldring CE; Park BK
Mol Cancer; 2011 Apr; 10():37. PubMed ID: 21489257
[TBL] [Abstract][Full Text] [Related]
17. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies.
Torres MP; Ponnusamy MP; Chakraborty S; Smith LM; Das S; Arafat HA; Batra SK
Mol Cancer Ther; 2010 May; 9(5):1419-31. PubMed ID: 20423995
[TBL] [Abstract][Full Text] [Related]
18. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
Mimeault M; Johansson SL; Senapati S; Momi N; Chakraborty S; Batra SK
Cancer Lett; 2010 Sep; 295(1):69-84. PubMed ID: 20303649
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.
Mimeault M; Batra SK
Anticancer Agents Med Chem; 2010 Feb; 10(2):137-51. PubMed ID: 20184544
[TBL] [Abstract][Full Text] [Related]
20. Targeted drug delivery in pancreatic cancer.
Yu X; Zhang Y; Chen C; Yao Q; Li M
Biochim Biophys Acta; 2010 Jan; 1805(1):97-104. PubMed ID: 19853645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
